It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery accelerates drug discovery in Immunology and Inflammation by combining deep scientific expertise with collaborative, data-driven approaches. Our integrated teams design bespoke assay cascades and translational models that help biotech and pharma partners move from insight to clinical reality faster and more effectively.
Immunology and inflammation are central to understanding a wide range of diseases- from autoimmune disorders and allergies to cancer and neurodegenerative conditions. When immune responses go off track, disease progression accelerates, making these pathways critical targets for therapy.
At Sygnature Discovery, we focus on creating smarter ways to modulate immune and inflammatory pathways. Our scientists work side by side with clients to design and execute tailored assay cascades that support discovery from early screening through in vivo proof-of-concept. By combining bioscience with medicinal chemistry and DMPK, we deliver connected solutions that move candidates toward clinical success.
Inflammation Assay Platforms
Our capabilities include immune cell activation models, intracellular signaling modulation, gene expression and functional assays, immunophenotyping, differentiation of naïve cells, and custom assay development for innate and adaptive immunity.
Immune Cell Activation Models
Monocyte-macrophage, neutrophil, NK, T & B cell, dendritic, innate lymphoid, PBMC, and whole blood models.
Intracellular Signalling
Calcium, cAMP, and phosphoprotein modulation.
Gene Expression & Functional Assays
Proliferation, chemotaxis, cytokine release, NETosis, pyroptosis, metabolism, and gene modulation
Immunophenotyping
Flow cytometry and imaging for immune cell subsets.
Our bioscience team develops in vitro immune cell assays to evaluate biomarkers, mechanisms, and endpoints with translational relevance. Using our in-house blood donor panel, we provide whole blood, PBMCs, and immune cell subsets from healthy donors, and source patient-derived samples through trusted networks.
To complement these assays, we offer access to validated in vivo models that support translational research across multiple indications, including systemic and neuro inflammation, neuropathy, arthritis, pain, IBD, and dermatitis.
Why Choose Sygnature Discovery for Inflammation and Immunology Support?
We offer an integrated approach to immunology and inflammation research. Our cross-functional teams combine bespoke assay development with expertise in bioscience, chemistry, and DMPK to deliver insights that accelerate drug discovery.
